HYPNOsis in the Management of Atopic Dermatitis in Children and Teenagers

Last updated: November 19, 2024
Sponsor: Centre Hospitalier Universitaire de la Réunion
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dermatitis, Atopic

Rash

Eczema (Atopic Dermatitis - Pediatric)

Treatment

Hypnosis

Clinical Study ID

NCT05611346
2022/CHU/15
  • Ages 8-17
  • All Genders

Study Summary

Atopic dermatitis (AD) is a chronic inflammatory dermatosis, common in children. It causes pruritus and skin lesions that can have a significant impact on patients' quality of life. AD can be difficult to treat because of its chronicity, demanding local care, corticophobia and the financial cost of non-reimbursed products. Patients are often looking for therapeutic alternatives. Medical hypnosis is a therapeutic alternative via hypnoanalgesia induced by direct suggestions of comfort and skin soothing and via anxiolysis, by working on stress management and self-esteem reinforcement. Four studies are interested in its action in AD and seem to show a reduction in pruritus, skin pain, an improvement in the intensity of atopic dermatitis, sleep, mood and for some a cure of AD. These results are encouraging but limited by the absence of a control group or by the small population included. Therefore, we propose in a first step to evaluate the feasibility of an hypnosis program through a pilot study, designed in the miniature format of a future, larger scale, randomized controlled trial.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children aged 8 to 17 years

  • Understanding french

  • With moderate to severe AD clinically diagnosed by a physician (SCORing AtopicDermatitis (SCORAD) ≥ 25)

  • Referred by their referring physician in the Reunionese therapeutic educationprogram for AD provided within the atopy school of the Reunion University Hospital.

  • Oral consent of the child and of one of the legal representatives collected.

Exclusion

Exclusion Criteria:

  • Children refusing to participate in the hypnosis session

  • Not having the possibility to listen to an audio file,

  • Already practicing self-hypnosis for their AD before inclusion,

  • Having a contraindication to hypnosis (psychiatric disorders, psychosis)

  • Treated by a systemic treatment for their AD.

Study Design

Total Participants: 32
Treatment Group(s): 1
Primary Treatment: Hypnosis
Phase:
Study Start date:
August 13, 2024
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • CHU de la Réunion

    Saint-Denis, 97400
    Réunion

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.